Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04035486 · MORE INFO

Limitations, agreements, and source contact

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) · Source last updated 2026-09-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The Investigator agrees to submit all manuscripts or abstracts to the sponsor before submission for publication or presentation at scientific meetings to allow the sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca
phone
1-877-240-9479
title
Global Clinical Lead
Complete source fields
certain Agreement
other Details
The Investigator agrees to submit all manuscripts or abstracts to the sponsor before submission for publication or presentation at scientific meetings to allow the sponsor to protect proprietary information and to provide comments.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
information.center@astrazeneca.com
organization
AstraZeneca
phone
1-877-240-9479
title
Global Clinical Lead

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice